IDO1 and neoplasm: Of the 122 remaining patients, corresponding to 259 evaluable tumor specimens, we analyzed IDO-1-expression by IHC in tumor cells, resulting in 84 patients (67.7%) IHC-negative (IHC-) and 40 patients (32.3%) IHC-positive (IHC+).